DELEX Pharma International Inc. (DELEX Pharma) proudly announces its groundbreaking partnership with Masimo, a global leader in innovative noninvasive monitoring technologies, and a trusted name of intensive care unit and medical device solutions in the Philippines.
The Philippines has seen rapid growth in the market for hemodynamic monitoring devices, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and an aging population. Meanwhile, the country’s brain monitoring devices market is expected to expand significantly through 2029, highlighting the urgent need for innovative solutions in critical care.
Through this partnership, DELEX Pharma aims to meet the growing demand by introducing Masimos state-of-the-art technologies to healthcare professionals and institutions across the country. This collaboration is projected to contribute to 30% of DELEX Pharma International Inc.s total revenue. The CEO and Chairman of the Board, Mr. J. de Ruyter Oroceo, stated, DELEXs expertise and strong leadership in anesthesia and critical care make this collaboration a strategic fit, benefiting both companies.
Masimos portfolio of hemodynamic monitoring solutions delivers unparalleled accuracy and insights, empowering clinicians to optimize fluid management and improve patient outcomes in critical care and surgical environments. Additionally, SedLine® brain function monitoring provides robust tools for assessing brain activity under sedation and anesthesia, addressing a critical need in modern medicine. Considering regulatory approvals for new products, the launch is projected for the third quarter of 2025.
Aligned with DELEX Pharmas mission of Meeting the Gaps in Critical Care, this business agreement will empower healthcare providers with the tools they need to deliver superior care in intensive care units, operating rooms, and other high-stakes medical settings.
For more information on Masimos innovative products or DELEX Pharmas critical care solutions, please contact: www.delexpharma.com
DELEX is a Delaware-registered company engaged in the development and distribution of pharmaceutical and healthcare products through its associate channels, DELEX Pharma, in collaboration with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc. DELEX focuses on delivering high-quality products across various sectors of the healthcare industry by leveraging its extensive network and strategic partnerships. Together with its associates, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit: https://delexhealth.com
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potential, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
